Harrow (HROW) reported first-quarter revenues of $44.2 million, marking a challenging start to 2026, as anticipated. The company faced an $8 million revenue reduction tied to VEVYE due to gross-to-net dynamics related to high-deductible patient mixes. Despite this setback, Harrow’s management emphasized strong demand trends across its key products, including VEVYE, IHEEZO, and TRIESENCE, which are expected to drive growth moving forward.
The implications for investors are significant. Harrow’s sequential growth in new prescriptions and market share gains indicate a robust demand environment, particularly for VEVYE, which has surpassed competitor XIIDRA in total prescriptions. The company has also expanded its sales force, doubling or tripling teams in key areas, which should enhance sales execution and revenue generation. With full-year revenue guidance reaffirmed at $350 million to $365 million, Harrow is positioning itself for sustained growth.
As the company prepares for upcoming product launches and reimbursement changes, investors should monitor Harrow’s ability to convert its strong demand signals into financial performance, particularly as it navigates the typical seasonal challenges of the second quarter.
Source: fool.com